SynthesisFrontiers in oncology2025
Association between ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphisms and gynecological cancer susceptibility: a meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of human papillomavirus (HPV) variants and host genetic susceptibility in cervical carcinogenesis.Archives of microbiology · 2026Review
- Exome-Based Identification of Candidate Genes in Sporadic Adenomyosis Cases.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gynecological tumors are diseases that pose serious threats to women's health. Cervical, endometrial, and ovarian cancers are the most common gynecologic tumors. Excision repair cross-complementation group 2 (ERCC2) plays a critical role in nucleotide excision repair. Polymorphisms in ERCC2 can influence DNA damage repair mechanisms, potentially increasing susceptibility to tumors. However, several studies have investigated the association between ERCC2 polymorphisms and the risk of gynecological tumors, but the results have been inconsistent. Therefore, we performed this meta-analysis to estimate these associations more precisely. Object: In this paper, we summarized a larger sample for meta-analysis to explored the relationship between the polymorphisms of the ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg and gynecological tumors. Methods: We conducted a systematic search for relevant case-control studies in PubMed, the Cochrane Library, Embase, and the Web of Science databases, covering studies up to October 2024. The odds ratio (OR) and its 95% confidence interval (CI) were calculated using Stata 17 software. Results: Finally, a total of 19 studies (9433 cases and 13144 controls) were included. 17 studies (3742 cases and 5591 controls) were conducted on the Lys751Gln polymorphism. Additionally, 9 studies(2,170 cases and 3,582 controls)were available for the Asp312Asn polymorphism, while 8 studies (3,521 cases and 3,971 controls)were included for the Arg156Arg polymorphism. Of these, 16 focused on ovarian cancer, 8 on cervical cancer, and 10 on endometrial cancer. The ERCC2 Lys751Gln polymorphism was found to increase the risk of gynecologic neoplasms(C vs A:OR 1.33, 95% CI 1.06-1.66;CC+CA vs AA:OR 1.33, 95% CI 1.11-1.59). Subgroup analysis by cancer type indicated an association of the Lys751Gln polymorphism with the development of ovarian cancer (CC+CA vs AA:OR 1.39, 95% CI 1.04-1.86), while no significant correlation was observed with cervical and endometrial cancers. Further subgroup analyses revealed that the Lys751Gln polymorphism increased the risk of gynecologic neoplasms in Caucasian and African populations, as well as in hospital-based studies. In contrast, the ERCC2 Asp312Asn polymorphism did not elevate the risk of gynecologic neoplasms, and the recessive gene variant was even protective against cervical cancer (AA vs GA+GG : OR 0.53, 95%CI 0.34-0.83, P=0.005). Additionally, this study did not find an association between the Arg156Arg polymorphism and susceptibility to gynecologic tumors. Conclusion: The ERCC2 Lys751Gln polymorphism is associated with an increased risk of gynecological tumors, particularly ovarian cancer. However, the Asp312Asn and Arg156Arg polymorphisms do not appear to elevate susceptibility to gynecological tumors. Even the recessive gene model of Asp312Asn polymorphism may have a protective effect on cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.